Revenue: As of FY2025 Q2, the actual value is USD 605.45 K.EPS: As of FY2025 Q2, the actual value is USD 0.<h3>Segment Revenue</h3><ul><li>Allergy Diagnostic Kit Sales: $197,644 for the three months ended June 30, 2025, compared to $190,994 for the same period in 2024. For the six months ended June 30, 2025, sales were $462,557 compared to $428,060 for the same period in 2024.</li><li>Integrated Service Program: $263,628 for the three months ended June 30, 2025, compared to $160,448 for the same period in 2024. For the six months ended June 30, 2025, sales were $426,130 compared to $287,452 for the same period in 2024.</li><li>Immunotherapy Treatment Sales: $119,885 for the three months ended June 30, 2025, compared to $92,482 for the same period in 2024. For the six months ended June 30, 2025, sales were $217,214 compared to $178,807 for the same period in 2024.</li><li>Clinical Study Revenue: $89,100 for the six months ended June 30, 2025, with no comparable revenue in 2024.</li><li>Subscription Revenue: $9,252 for the three months ended June 30, 2025, compared to $14,339 for the same period in 2024. For the six months ended June 30, 2025, revenue was $18,537 compared to $32,709 for the same period in 2024.</li><li>Shipping and Handling: $10,091 for the three months ended June 30, 2025, compared to $8,861 for the same period in 2024. For the six months ended June 30, 2025, revenue was $20,061 compared to $18,820 for the same period in 2024.</li><li>Training and Other Revenue: $4,946 for the three months ended June 30, 2025, compared to $5,949 for the same period in 2024. For the six months ended June 30, 2025, revenue was $17,266 compared to $15,812 for the same period in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Gross Profit: $399,015 for the three months ended June 30, 2025, compared to $294,445 for the same period in 2024. For the six months ended June 30, 2025, gross profit was $828,959 compared to $580,603 for the same period in 2024.</li><li>Gross Margin: 65.9% for the three months ended June 30, 2025, compared to 62.2% for the same period in 2024. For the six months ended June 30, 2025, gross margin was 66.3% compared to 60.4% for the same period in 2024.</li><li>Sales and Marketing Expenses: $158,447 for the three months ended June 30, 2025, compared to $134,183 for the same period in 2024. For the six months ended June 30, 2025, expenses were $302,846 compared to $256,129 for the same period in 2024.</li><li>General and Administrative Expenses: $98,650 for the three months ended June 30, 2025, compared to $47,455 for the same period in 2024. For the six months ended June 30, 2025, expenses were $254,173 compared to $137,397 for the same period in 2024.</li><li>Research and Development Expenses: $112,364 for the three months ended June 30, 2025, compared to $64,812 for the same period in 2024. For the six months ended June 30, 2025, expenses were $236,397 compared to $107,450 for the same period in 2024.</li><li>Interest Expense: $64,484 for the three months ended June 30, 2025, compared to $32,857 for the same period in 2024. For the six months ended June 30, 2025, interest expense was $132,054 compared to $64,986 for the same period in 2024.</li><li>Net Loss: $52,958 for the three months ended June 30, 2025, compared to $2,890 for the same period in 2024. For the six months ended June 30, 2025, net loss was $132,567 compared to $21,415 for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Operating Cash Flow: $77,484 for the six months ended June 30, 2025, compared to $143,961 for the same period in 2024.</li><li>Financing Cash Flow: -$66,294 for the six months ended June 30, 2025, compared to -$91,343 for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to increase revenues by charging physicians a monthly subscription fee for the use of QHSLab and soliciting additional PCPs to increase their revenues by using QHSLab and AllergiEnd products. The company also plans to introduce additional point of care diagnostics and treatments, and digital medicine programs that PCPs can use and prescribe in their practices.</li><li>Non-Core Business: The company is in default under its OID Notes and Acquisition Note and is engaging in discussions with Catheter to restructure the OID Notes. The company is also exploring options to raise additional capital or borrow additional funds on favorable terms.</li></ul>

QHSLab, Inc. | 10-Q: FY2025 Q2 Revenue: USD 605.45 K